7.59
前日終値:
$8.04
開ける:
$8.1
24時間の取引高:
3.23M
Relative Volume:
1.91
時価総額:
$521.98M
収益:
$161.10M
当期純損益:
$-308.60M
株価収益率:
-1.6253
EPS:
-4.67
ネットキャッシュフロー:
$-259.90M
1週間 パフォーマンス:
-13.26%
1か月 パフォーマンス:
-56.03%
6か月 パフォーマンス:
-69.32%
1年 パフォーマンス:
-81.61%
Arvinas Inc Stock (ARVN) Company Profile
ARVN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ARVN
Arvinas Inc
|
7.59 | 521.98M | 161.10M | -308.60M | -259.90M | -4.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-13 | ダウングレード | Goldman | Buy → Neutral |
2025-03-12 | ダウングレード | Wedbush | Outperform → Neutral |
2025-03-11 | ダウングレード | Oppenheimer | Outperform → Perform |
2024-12-10 | 開始されました | BTIG Research | Buy |
2024-11-18 | 開始されました | Stephens | Overweight |
2024-02-28 | 繰り返されました | Oppenheimer | Outperform |
2024-02-14 | ダウングレード | Citigroup | Buy → Neutral |
2024-02-01 | 開始されました | Goldman | Buy |
2023-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2023-12-06 | アップグレード | Jefferies | Hold → Buy |
2023-11-20 | アップグレード | Guggenheim | Neutral → Buy |
2023-10-23 | アップグレード | Wedbush | Neutral → Outperform |
2023-06-26 | 再開されました | Oppenheimer | Outperform |
2023-01-12 | ダウングレード | Guggenheim | Buy → Neutral |
2023-01-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2022-09-09 | 開始されました | Barclays | Overweight |
2022-06-21 | 開始されました | Jefferies | Hold |
2022-05-09 | ダウングレード | Wedbush | Outperform → Neutral |
2022-04-28 | 開始されました | Credit Suisse | Outperform |
2022-04-06 | 開始されました | Morgan Stanley | Equal-Weight |
2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
2022-02-10 | 開始されました | Wells Fargo | Overweight |
2022-01-19 | 開始されました | Goldman | Buy |
2021-12-07 | 開始されました | Cowen | Outperform |
2021-10-14 | 開始されました | SVB Leerink | Outperform |
2021-09-30 | 開始されました | Stifel | Buy |
2021-09-09 | 開始されました | BofA Securities | Buy |
2021-05-21 | 開始されました | UBS | Buy |
2021-04-21 | 開始されました | Truist | Buy |
2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
2020-12-14 | アップグレード | Oppenheimer | Perform → Outperform |
2020-06-01 | アップグレード | Citigroup | Neutral → Buy |
2020-05-12 | 開始されました | Oppenheimer | Perform |
2019-12-19 | 開始されました | H.C. Wainwright | Buy |
2019-11-25 | 開始されました | Guggenheim | Buy |
2019-10-24 | アップグレード | Goldman | Neutral → Buy |
2019-09-25 | 開始されました | Wedbush | Outperform |
2019-09-12 | 開始されました | BMO Capital Markets | Outperform |
2019-08-06 | 開始されました | Cantor Fitzgerald | Overweight |
2019-06-05 | ダウングレード | Citigroup | Buy → Neutral |
2019-04-12 | 開始されました | Evercore ISI | Outperform |
2018-10-22 | 開始されました | Citigroup | Buy |
2018-10-22 | 開始されました | Goldman | Neutral |
2018-10-22 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Arvinas Inc (ARVN) 最新ニュース
Arvinas (NASDAQ:ARVN) Reaches New 52-Week LowHere's What Happened - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by BIT Capital GmbH - MarketBeat
Arvinas stock hits 52-week low at $7.91 amid market challenges - Investing.com India
Arvinas stock hits 52-week low at $7.91 amid market challenges By Investing.com - Investing.com South Africa
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases - GlobeNewswire
Groundbreaking First Human Data: New PROTAC Drug Takes Aim at Parkinson's Disease - StockTitan
Arvinas (NASDAQ:ARVN) Shares Down 5.1%Time to Sell? - MarketBeat
Arvinas FY2025 EPS Forecast Increased by Cantor Fitzgerald - MarketBeat
Noah Berkowitz Sells 8,658 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock - MarketBeat
Arvinas (NASDAQ:ARVN) Trading Up 4%Here's Why - MarketBeat
Wedbush Brokers Raise Earnings Estimates for Arvinas - MarketBeat
Wedbush Has Positive Outlook for Arvinas Q1 Earnings - MarketBeat
Arvinas chief medical officer sells $74,372 in common stock By Investing.com - Investing.com South Africa
Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Yahoo Finance
Arvinas chief medical officer sells $74,372 in common stock - Investing.com India
Arvinas Chief Medical Officer Sells Shares to Cover Tax Obligations - TradingView
(ARVN) Technical Pivots with Risk Controls - Stock Traders Daily
Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds? - Yahoo Finance
Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook By Investing.com - Investing.com Australia
Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook - Investing.com
Arvinas (NASDAQ:ARVN) Price Target Cut to $12.00 by Analysts at Morgan Stanley - MarketBeat
Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Yahoo Finance
Guggenheim Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Arvinas (NASDAQ:ARVN) Rating Lowered to Neutral at The Goldman Sachs Group - MarketBeat
Arvinas (NASDAQ:ARVN) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Arvinas (NASDAQ:ARVN) Given New $28.00 Price Target at Bank of America - MarketBeat
Arvinas (NASDAQ:ARVN) Hits New 1-Year LowHere's What Happened - MarketBeat
Oppenheimer Downgrades Arvinas (NASDAQ:ARVN) to Market Perform - MarketBeat
Arvinas' (ARVN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Arvinas Plunges 45% After Pfizer-Partnered Drug Disappoints - MSN
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J - Yahoo Finance
Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects - Seeking Alpha
Arvinas’s SWOT analysis: biotech stock faces pivotal trials amid competition By Investing.com - Investing.com South Africa
Bank of America Lowers Arvinas (NASDAQ:ARVN) Price Target to $28.00 - Defense World
Arvinas (NASDAQ:ARVN) Stock Rating Lowered by Wedbush - Defense World
Arvinas Plunges 40% After Pfizer-Partnered Drug Disappoints - MSN
Arvinas Inc Reports Q4 2024 EPS of -$0.63, Beating Estimates, Re - GuruFocus.com
Arvinas Inc (ARVN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):